Hemal Mehta, MD
Internal Medicine · Brooklyn, NYNPI 1720326564
Payments from drug & device makers
Across 186 payments — averaging $130.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$21K
- Boston Scientific$784
- GSK$550
- United Therapeutics Corporation$260
- Regeneron Healthcare Solutions, Inc.$157
- Inspire Medical Systems, Inc.$127
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$16,37067%
- Travel & lodging$2,78111%
- Food & beverage$5,11021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $21,130 |
| Boston Scientific | 4 | $784 |
| GSK | 29 | $550 |
| United Therapeutics Corporation | 11 | $260 |
| Regeneron Healthcare Solutions, Inc. | 10 | $157 |
| Inspire Medical Systems, Inc. | 5 | $127 |
| Pulmonx Corporation | 1 | $119 |
| Sanofi | 6 | $102 |
| Harmony Biosciences LLC | 5 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $89 |
| Mylan Specialty L.p. | 5 | $83 |
| Amgen | 5 | $76 |
| Boehringer Ingelheim | 4 | $67 |
| Electromed, Inc. | 5 | $59 |
| Insmed, Inc. | 3 | $58 |
| Philips North America LLC | 3 | $55 |
| AbbVie | 3 | $45 |
| Argenx US, Inc. | 2 | $37 |
| Viatris Specialty LLC | 2 | $36 |
| Genentech USA, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 2 | $32 |
| Tactile Systems Technology Inc | 1 | $29 |
| Lilly USA, LLC | 1 | $22 |
| SK Life Science, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Inogen, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$19,885
- ULTRAFLEX$546
- FASENRA$391
- BREZTRI$269
- GENERAL PULMONARY$132
- AIRSUPRA$132
- TYVASO$125
- CHARTIS CATHETER$119
- ZEPHYR DELIVERY CATHETER$119
- ZEPHYR ENDOBRONCHIAL VALVE$119
- PULMONX CHARTIS TABLET CONSOLE$119
- AREXVY$108
How this compares
$24,260 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 233 | $223,021 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 101 | $60,577 |
| Dupixent PenDupilumab | 16 | $58,880 |
| TezspireTezepelumab-Ekko | 13 | $52,633 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $44,915 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $40,141 |
| Spiriva RespimatTiotropium Bromide | 26 | $19,983 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $18,524 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $11,963 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $4,123 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,448 |
| Mycophenolate Mofetil | 42 | $3,385 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $2,942 |
| Mometasone Furoate | 13 | $708 |
| Montelukast Sodium | 28 | $382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $550 | $323,739410 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $21,130 | $109,510113 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $67 | $38,50763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.